Reviving the FDA: NEJM perspective

Oct 06, 2010

In a Perspective piece published online today in the New England Journal of Medicine, Georgetown University School of Medicine family medicine physician Susan Okie gives a comprehensive overview of change, and planned change, within the Food and Drug Administration (FDA). The review comes as the FDA's commissioner, Margaret Hamburg, completes her first year as the agency's leader.

Okie writes that the FDA's priorities over the past year have included "finding ways to make the FDA more nimble and proactive, restoring its and refocusing staff on its public health mission, persuading Congress to boost funding for its expanding portfolio of responsibilities, [and] sharpening its ability to deal with new science and globalization…"

To that end, Hamburg reportedly has spent hundreds of hours meeting with interest groups and meeting with key members of Congress to build alliances.

As Okie outlines, Hamburg and the deputy commissioner, Joshua Sharfstein, have already undertaken several changes at the agency. The two leaders have met with FDA employees to understand hurdles they encounter because of legal and regulatory requirements. Such discussions have prompted new measures to accelerate responses to urgent health threats. In nonemergency situations, changes that have been described as "nuanced" actions often achieve desired results, Sharfstein says.

Hamburg, Sharfstein and internal task forces have been "reexamining the processes for making decisions" about the safety and effectiveness of drugs and medical devices. Okie says the agency is awaiting reports next year by Institute of Medicine panels that are likely to recommend reforms. The leadership anticipates decisions that could lead to lasting changes at the agency.

Finally, Hamburg's longer-term priorities include regulatory science and globalization. The Commissioner tells Okie that in addition to advocating for increased funding, the agency hopes to collaborate with scientists in academia and industry, as well as other federal health agencies, on research and training in areas such as biomarker, bioimaging, clinical-trial analytics and pharmacoepidemiology.

As for , Okie reports that the agency is introducing a risk-based strategy for targeting priority inspections in order to "grapple with the expanding task of ensuring the safety of products… made overseas."

Hamburg says despite the criticism of her agency and the growing pains within "...overseas, the FDA is still considered the gold standard for a regulatory agency," while here at home she says, "I have encountered a sense of real eagerness... to support the FDA in its mission."

Explore further: Medtronic spends $350M on another European deal

add to favorites email to friend print save as pdf

Related Stories

FDA stresses need to modernize its science

Oct 06, 2010

(AP) -- The Food and Drug Administration must update its scientific tools for reviewing prescription drugs, medical devices and tracking food safety, according to a list of priorities laid out Wednesday by agency leadership.

FDA Web site explains agency operations to public

Jan 12, 2010

(AP) -- The Food and Drug Administration is launching a new Web site explaining its operations to consumers as part of a broader effort to rebrand itself as a more accessible agency.

New FDA chiefs stress science, better food safety

May 26, 2009

(AP) -- The huge salmonella outbreak from peanut butter represented a failure of the Food and Drug Administration, that agency's new chiefs declared Tuesday - one they hope to fix.

FDA drug approvals mostly flat in 2009

Jan 05, 2010

(AP) -- Drug approvals from the Food and Drug Administration were flat last year compared with 2008 and warnings fell, even as the agency's new leadership struck a tougher stance on safety.

Drug industry advocates join chorus to split FDA

Mar 22, 2009

(AP) -- As momentum builds to rework the nation's food-safety system after a salmonella outbreak linked to peanuts, the drug industry is hoping for a happy side effect: faster approvals for new medicines.

Recommended for you

Medtronic spends $350M on another European deal

9 hours ago

U.S. medical device maker Medtronic is building stronger ties to Europe, a couple months after announcing a $42.9 billion acquisition that involves moving its main executive offices across the Atlantic, where it can get a ...

Mind over matter for people with disabilities

Aug 26, 2014

People with serious physical disabilities are unable to do the everyday things that most of us take for granted despite having the will – and the brainpower – to do so. This is changing thanks to European ...

Ukraine's former world's tallest man dies

Aug 25, 2014

Ukraine's tallest man, who briefly held the world record but gave it up to live as a recluse, has died due to complications from the condition that saw him never stop growing, local media reported Monday.

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

Justsayin
not rated yet Oct 16, 2010
"boost funding" appears multiple times in this article but when you give more money to an incompetent and corrupt agency you get more incompetence and corruption. The FDA stifles new cancer drug development, delay approvals driving up the costs to astronomical levels and with all of these delays what is the real cost in lives. The story of 19 year old Abigail Burroughs says it all here...http://www.abigai...tory.php
Justsayin
not rated yet Oct 16, 2010
this is the link I meant to post http://www.lef.or...s_01.htm